Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 205
- Registration Number
- NCT00179621
- Locations
- 🇧🇪
AZ St-Jan Brugge AV, Brugge, Belgium
🇧🇪UZ Gasthuisberg, Leuven, Belgium
🇧🇪CHU Mont Godine, Yvoir, Belgium
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT00179712
- Locations
- 🇺🇸
Medical College of GeorgiaDept of OBGYN, Augusta, Georgia, United States
🇺🇸University of MinnesotaObstetrics & Gynecology, MMC, Minneapolis, Minnesota, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2010-03-16
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 1913
- Registration Number
- NCT00179647
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Cedar Sinai Medical CenterDept of Medicine, Los Angeles, California, United States
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 28
- Registration Number
- NCT00179608
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 16
- Registration Number
- NCT00140140
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸City of Hope Comprehensive Cancer Care Center, Duarte, California, United States
Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
- Conditions
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2007-05-15
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT00126893
- Locations
- 🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States
Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
- First Posted Date
- 2005-07-29
- Last Posted Date
- 2012-04-02
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 112
- Registration Number
- NCT00124943
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy
- First Posted Date
- 2005-07-15
- Last Posted Date
- 2009-09-23
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 181
- Registration Number
- NCT00120120
- Locations
- 🇺🇸
Loma Linda Institution, Loma Linda, California, United States
🇺🇸Washington University Pain Mgmt Ctr, St. Louis, Missouri, United States
🇺🇸Texas Tech Medical Center Department of Anesthesiology, Lubbock, Texas, United States
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1
- Conditions
- Interventions
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 184
- Registration Number
- NCT00109772
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Washington University Pain Mgmt Ctr, St. Louis, Missouri, United States
🇺🇸Lehigh Valley Hospital, Allentown, Pennsylvania, United States
Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer
- Conditions
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2007-07-20
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT00107094
- Locations
- 🇺🇸
Abraxis BioScience Inc., Durham, North Carolina, United States